MYC and neoplasm: Diclofenac, a non-steroidal anti-inflammatory drug, has recently shown the ability to inhibit GLUT-1, LDH-A, and MCT1 expression in cancer cell lines, along with decreased MYC activity, resulting in reduced cell proliferation and tumor growth [58].